within Pharmacolibrary.Drugs.ATC.S;

model S01LA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.004233333333333334,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.00289,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor, used primarily for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and other retinal vascular diseases. It is approved for intravitreal use in ophthalmology.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after a single intravitreal injection of aflibercept 2 mg in adult patients with neovascular AMD; population includes both sexes, typically age >50 years.</p><h4>References</h4><ol><li><p>Avery, RL, et al., &amp; Hanley, WD (2017). SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. <i>Retina (Philadelphia, Pa.)</i> 37(10) 1847–1858. DOI:<a href=&quot;https://doi.org/10.1097/IAE.0000000000001493&quot;>10.1097/IAE.0000000000001493</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28106709/&quot;>https://pubmed.ncbi.nlm.nih.gov/28106709</a></p></li><li><p>Park, SJ, et al., &amp; Woo, SJ (2016). Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model. <i>Investigative ophthalmology &amp; visual science</i> 57(6) 2612–2617. DOI:<a href=&quot;https://doi.org/10.1167/iovs.16-19204&quot;>10.1167/iovs.16-19204</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27258433/&quot;>https://pubmed.ncbi.nlm.nih.gov/27258433</a></p></li><li><p>García-Quintanilla, L, et al., &amp; Fernández-Ferreiro, A (2019). Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. <i>Pharmaceutics</i> 11(8) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics11080365&quot;>10.3390/pharmaceutics11080365</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31370346/&quot;>https://pubmed.ncbi.nlm.nih.gov/31370346</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01LA05;
